Cyna Pharma: Reaping the Rewards of Perseverance (B)
Case Study

Cyna Pharma: Reaping the Rewards of Perseverance (B)

5 pages
January 2022
Reference: IMD-7-2317

The B case describes the events – including the offers and the negotiation – leading up to Sundown’s acquisition of Cyna for US$40.50 per share in cash or US$624 million (approximately C$841 million) – a 120% premium over the closing price of just over US$18 a share before the deal was announced.The case also brings the reader up to date on the turns Anthony’s life has taken since the acquisition and some of the exciting ventures in which he is now involved.

Learning Objective

• Managing growth in a biopharma company
• Leadership in a pharma company, from start-up to listed firm and trade sale
• Developing resilience in a firm – Managing risk

Keywords
Finance, Finance Leadership, Leadership
Settings
America, Canada
Cyna Pharma (Disguised), Pharmaceuticals
2002-2016
Type
Field Research
Copyright
© IMD 2022
Language
English
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre, UK Office

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Fax +44 (0)1234 751125
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

The Case Centre, US office

Babson College

Babson Park, Wellesley MA 02457, USA
Tel +1 781 239 5884
Fax +1 781 239 5885
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Looking for something specific?
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics